ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ELAFIBRANOR WITH INDOMETHACIN IN HEALTHY ADULT MALE PARTICIPANTS: AN OPEN-LABEL PHASE I TRIAL

被引：0
|
作者：
Pedret-Dunn, Anna
Mazain, Sarah
Allan, Richard
Gattolliat, Olivier
Hanf, Remy
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1591
引用
收藏
页码：S1705 / S1706
页数：2
相关论文
共 50 条
  • [41] AN OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETIC DRUG-DRUG INTERACTION BETWEEN RAMELTEON 8 mg AND LORAZEPAM 4 mg IN NORMAL HEALTHY ADULTS
    Karim, A.
    Waldron, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S84 - S84
  • [42] Impact on abiraterone pharmacokinetics (PK) and safety: Open-label drug-drug interaction (DDI) studies with ketoconazole and rifampicin
    Chien, C.
    Bernard, A.
    Vaccaro, N.
    Acharya, M.
    Jiao, J.
    Monbaliu, J.
    De Vries, R.
    Stieltjes, H.
    Yu, M. K.
    Tran, N. P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S702 - S703
  • [43] SAFETY, TOLERABILITY, AND PHARMACOKINETIC EFFECTS OF ELAFIBRANOR CO-ADMINISTRATION WITH SIMVASTATIN: AN OPEN-LABEL PHASE I TRIAL
    Medical, Costello
    Miller, Benjamin
    Mazain, Sarah
    Hanf, Remy
    Addy, Carol
    HEPATOLOGY, 2023, 78 : S2072 - S2073
  • [44] Bidirectional Drug-Drug Interaction with Coadministration of Cannabidiol and Clobazam in a Phase 1 Healthy Volunteer Trial
    Knappertz, V.
    Sommerville, K.
    Crockett, J.
    Blakey, G. E.
    Morrison, G.
    EPILEPSIA, 2018, 59 : S11 - S11
  • [45] A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects
    Pang, Yanqing
    Li, Haijun
    Chen, Xuemei
    Cao, Yingying
    Jiang, Hui
    Huang, Jufang
    Liu, Yiming
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (04)
  • [46] Open-Label, Single-Dose, Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE609 (Cipargamin) and Piperaquine
    Stein, Daniel S.
    Jain, Jay Prakash
    Kangas, Michael
    Lefevre, Gilbert
    Machineni, Surendra
    Griffin, Paul
    Lickliter, Jason
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3493 - 3500
  • [47] Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial
    Wray, Louise
    Berwaerts, Joris
    Critchley, David
    Hyland, Kerry
    Chen, Cuiping
    Thai, Ching
    Tayo, Bola
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, : 911 - 919
  • [48] Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial
    Ye, Pan-Pan
    Yao, Bu-Fan
    Yang, Yang
    Yang, Xin-Mei
    Li, Qian
    Song, Lin-Lin
    Chen, Ke-Guang
    Zhou, Hai-Yan
    Shi, Jin-Yi
    Zhang, Ye-Hui
    Zhao, Fu-Rong
    Guo, Zi-jia
    Xu, Shan-sen
    Chen, Jia
    Goh, Aik Han
    Zhu, Shun-Wei
    Zheng, Yi
    Zhao, Wei
    CLINICAL MICROBIOLOGY AND INFECTION, 2025, 31 (01) : 101 - 107
  • [49] Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study
    Italo Poggesi
    Lilian Y. Li
    James Jiao
    Peter Hellemans
    Freya Rasschaert
    Loeckie de Zwart
    Jan Snoeys
    Marc De Meulder
    Rao N. V. S. Mamidi
    Daniele Ouellet
    European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45 : 101 - 111
  • [50] A Phase 2 Trial to Explore the Potential for a Pharmacokinetic Drug-Drug Interaction with Valproate When in Combination with Cannabidiol in Adult Epilepsy Patients
    Ben-Menachem, E.
    Gunning, B.
    Arenas Cabrera, C. M.
    Van Landingham, K.
    Crockett, J.
    Taylor, L.
    Critchley, D.
    Tayo, B.
    Morrison, G.
    Toledo, M.
    EPILEPSIA, 2018, 59 : S51 - S51
12345